HPV9 vaccine to be added to national immunisation schedules from January 2027

HPV9 will replace HPV2 for female students who have yet to start or complete their vaccination series under the Health Promotion Board's school-based programme.

A box of Gardasil 9 human papillomavirus virus (HPV) vaccine. (File photo: AFP/Patrick T Fallon)

Add CNA as a trusted source to help Google better understand and surface our content in search results.

SINGAPORE: The human papillomavirus 9-valent (HPV9) vaccine will be added to national immunisation schedules next year, health authorities said on Friday (Oct 2), giving eligible female Singaporeans and permanent residents broader protection against cervical cancer.

From Jan 1, 2027, the HPV9 vaccine will be added to the National Childhood Immunisation Schedule (NCIS), National Adult Immunisation Schedule (NAIS) and Subsidised Vaccine List (SVL), said the Ministry of Health (MOH), Health Promotion Board (HPB) and Communicable Diseases Agency (CDA) in a joint release.

“The HPV9 vaccine, also known as Gardasil 9, will be included in the NCIS and NAIS for females aged 9 to 26,” said the authorities. “The HPV2 vaccine, also known as Cervarix, will remain on both schedules as an alternative option.”

Human papillomavirus, or HPV, is the most common sexually transmitted infection worldwide, with nearly 80 per cent of men and women infected at some point in their lives. It can cause cervical cancer, as well as cancers of the anus, throat, vulva, vagina and penis.

本文の著作権はCNAにあります。